Skip to content
This GLP
Head to head

Trimi Health vs Pallas Health

A year paid up front against a quarter at a time, at the same rate.

By Dana SullivanEvidence reviewer

Trimi Health

Editorial

$99/mo

Trimi Health advertises $99 a month for compounded semaglutide and $125 for compounded tirzepatide, and bills both as an annual plan: $1,188 and $1,500, charged up front or split through a buy-now-pay-later provider. The rate is stated as flat across doses.

Pick it for: Readers who want the lowest rate and can fund the year

Pallas Health

Editorial

$216/mo

Pallas Health charges $139 for a first month of compounded semaglutide and $597 every twelve weeks after it, which the seller averages to $199 a month. Twelve weeks is 2.76 calendar months rather than three, so the figure ranked here is $216, and the $897 tirzepatide block works out at $325. Provider care and check-ins are described as included, and the rate is stated as the same at every dose.

Pick it for: Readers who want commitment in shorter blocks

Our verdict

Trimi Health asks for the annual plan in advance; Pallas Health bills every twelve weeks. The question is how much of the year a reader wants to owe on day one.

What actually separates them

Trimi Health and Pallas Health state different things about published price. Everything else they publish, they publish the same way.

Pallas Health costs $117 more than Trimi Health — 118% more for the same molecule. Whether that buys anything is what the rest of this page is for.

Over twelve months that is about $1,188 at Trimi Health against $2,592 at Pallas Health — a difference of $1,404.

 Trimi HealthPallas Health
Published price$99/mo$216/mo

Before you choose either

Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.

Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.

All head-to-head comparisons · The buyer’s guides